Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 2/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | TNK2 | Q07912 | 18/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL401929 | 0.90 | IGF1R (0.77) | IGF1RCYP3A4TNK2 | |
| SCHEMBL400491 | 0.89 | IGF1R (0.66) | IGF1RCYP3A4TNK2 | |
| SCHEMBL10225365 | 0.85 | IGF1R (0.64) | IGF1RCYP3A4TNK2 | |
| SCHEMBL401395 | 0.85 | IGF1R (0.62) | IGF1RCYP3A4TNK2 | |
| Carbamic Acid SCHEMBL4063099 | 0.85 | IGF1R (0.69) | IGF1RCYP3A4TNK2 | |
| SCHEMBL11895445 | 0.84 | IGF1R (0.68) | IGF1RCYP3A4TNK2 | |
| SCHEMBL13128500 | 0.84 | IGF1R (0.68) | IGF1RCYP3A4TNK2 | |
| Carbamic Acid SCHEMBL4060715 | 0.83 | IGF1R (0.61) | IGF1RCYP3A4TNK2 | |
| SCHEMBL13447994 | 0.82 | IGF1R (0.65) | IGF1RCYP3A4TNK2 | |
| SCHEMBL397715 | 0.82 | IGF1R (0.69) | IGF1RCYP3A4TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735405-B2 | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2014-05-27 | — | — | US | disclosed |
| US-20120196847-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-08-02 | — | — | US | disclosed |
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077979-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | IGF1R 1/4885CYP3A4 1815/4885TNK2 405/4885 |
| US-20120196847-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | IGF1R 1/4885CYP3A4 1815/4885TNK2 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.